Who we are
Corticalis AS was founded in 2006 by leading researchers and clinicians with extensive experience developing and marketing dental implants and regenerative therapies. The company aims to develop its own innovative and sustainable medical devices for professional follow-up of patients treated for oral diseases and wounds on the skin and mucous membranes.
Corticalis places particular emphasis on creating and promoting alternatives to antibiotic-based antimicrobial agents. The increased use of antibiotics is causing bacteria and other microbes to become resistant to medication. Corticalis offers effective alternatives to antibiotics so that this problem can be avoided.
Today, the company has finished products for maintaining teeth and dental implants that are prone to gum disease. These products, developed with a focus on patient comfort and effectiveness, offer a comprehensive solution for oral health. Corticalis has also developed a nature-mimicking, non-animal product for surgically rebuilding supportive tissue around teeth and implants where it has been lost due to disease. These products will be marketed through a global network of established distributors.
During its development phase, Corticalis has undergone evaluations and received significant support from the Research Council of Norway and the European Union. The company has three times been awarded the European Commission’s “Seal of Excellence,” an essential confirmation of its projects and products' high quality and societal value.
Who we are
Corticalis AS was founded in 2006 by leading researchers and clinicians with extensive experience developing and marketing dental implants and regenerative therapies. The company aims to develop its own innovative and sustainable medical devices for professional follow-up of patients treated for oral diseases and wounds on the skin and mucous membranes.
Corticalis places particular emphasis on creating and promoting alternatives to antibiotic-based antimicrobial agents. The increased use of antibiotics is causing bacteria and other microbes to become resistant to medication. Corticalis offers effective alternatives to antibiotics so that this problem can be avoided.
Today, the company has finished products for maintaining teeth and dental implants that are prone to gum disease. These products, developed with a focus on patient comfort and effectiveness, offer a comprehensive solution for oral health. Corticalis has also developed a nature-mimicking, non-animal product for surgically rebuilding supportive tissue around teeth and implants where it has been lost due to disease. These products will be marketed through a global network of established distributors.
During its development phase, Corticalis has undergone evaluations and received significant support from the Research Council of Norway and the European Union. The company has three times been awarded the European Commission’s “Seal of Excellence,” an essential confirmation of its projects and products' high quality and societal value.
Who we are
Corticalis AS was founded in 2006 by leading researchers and clinicians with extensive experience developing and marketing dental implants and regenerative therapies. The company aims to develop its own innovative and sustainable medical devices for professional follow-up of patients treated for oral diseases and wounds on the skin and mucous membranes.
Corticalis places particular emphasis on creating and promoting alternatives to antibiotic-based antimicrobial agents. The increased use of antibiotics is causing bacteria and other microbes to become resistant to medication. Corticalis offers effective alternatives to antibiotics so that this problem can be avoided.
Today, the company has finished products for maintaining teeth and dental implants that are prone to gum disease. These products, developed with a focus on patient comfort and effectiveness, offer a comprehensive solution for oral health. Corticalis has also developed a nature-mimicking, non-animal product for surgically rebuilding supportive tissue around teeth and implants where it has been lost due to disease. These products will be marketed through a global network of established distributors.
During its development phase, Corticalis has undergone evaluations and received significant support from the Research Council of Norway and the European Union. The company has three times been awarded the European Commission’s “Seal of Excellence,” an essential confirmation of its projects and products' high quality and societal value.